Localized Extremity Soft Tissue Sarcoma: Improved Knowledge With Unchanged Survival Over Time
Abstract
Purpose The objective of this study was to define whether survival of patients with extremity soft tissue sarcoma (STS), stratified for known risk factors, has improved over the last 20 years. Patients and methods From January 1982 to December 2001, 1,706 patients with primary and recurrent STS of the extremities were treated at our institution and were prospectively followed. From this cohort, we selected 1,261 patients who underwent complete macroscopic resection and had one of the following histopathologies: fibrosarcoma, liposarcoma, leiomyosarcoma, malignant fibrous histiocytoma, or synovial sarcoma. Median follow-up was 55 months. Patient, tumor, and treatment factors were analyzed as prognostic factors. Results The 5-year disease-specific actuarial survival was 79% (78% for patients treated from 1982 to 1986, 79% for patients treated from 1986 to 1991, 79% for patients treated from 1992 to 1996, and 85% for patients treated from 1997 to 2001; P = not significant). For high-risk patients (high-grade, > 10 cm, deep tumors; n = 247), 5-year disease-specific survival was 51% (50% for patients treated from 1982 to 1986, 45% for patients treated from 1986 to 1991, 52% for patients treated from 1992 to 1996, and 61% for patients treated from 1997 to 2001; P = not significant). Tumor depth, size, grade, microscopic margin status, patient age, presentation status (primary tumor versus local recurrence), location (proximal versus distal), and certain histopathologic subtypes wer…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Recurrent, refractory and metastatic RMS represents one of the persistent clinical therapeutic challenges and unmet clinical need, with improvement in 5-year survival experiencing one of the smallest increases of all pediatric and AYA cancers.
“of which recurrent, refractory and metastatic RMS represents one of the persistent clinical therapeutic challenges and unmet clinical need,88–90 with improvement in 5-year survival experiencing one of the smallest increases of all pediatric and AYA cancers.91–95”
From Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation (2023) · cites this paper as [92]
The citation lists haven’t been fetched yet
References 22 · Cited by 365
- Authors
- Weitz, J., Antonescu, C. R., & Brennan, M. F.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Journal of Clinical Oncology
- Published
- 2003-07-15
- Volume
- 21
- Issue
- 14
- Pages
- 2719-2725
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1980715318
- Cited by
- 365
- References
- 22
- Citations by year
- 2026: 5 · 2025: 15 · 2024: 14 · 2023: 14 · 2022: 22 · 2021: 27 · 2020: 18 · 2019: 14 · 2018: 12 · 2017: 20 · 2016: 15 · 2015: 20 · 2014: 16 · 2013: 15 · 2012: 18
- FWCI
- 13.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion)
- Funders
- National Cancer Institute (CA 47179, P01CA047179)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Rheumatology › Soft tissue tumor case studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
- Keywords
- extremity soft tissue sarcoma, disease-specific survival, prognostic factors, depth of invasion, tumor size, tumor grade, local recurrence, treatment trends, liposarcoma, fibrosarcoma, malignant fibrous histiocytoma, synovial sarcoma, leiomyosarcoma
- MeSH terms
- Adult, Aged, Analysis of Variance, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Probability, Retrospective Studies, Risk Factors, Sarcoma, Soft Tissue Neoplasms, Cohort Studies, Proportional Hazards Models, Survival Analysis, Treatment Outcome, Chemotherapy, Adjuvant, Risk Assessment, Disease-Free Survival, Radiotherapy, Adjuvant, Orthopedic Procedures, Upper Extremity, Lower Extremity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review